Search results for "Trials"

showing 10 items of 966 documents

Use of Troponin as a predictor for cardiovascular diseases in patients with type 2 Diabetes Mellitus

2020

People with type 2 diabetes mellitus (T2DM) have two- to four-fold increased cardiovascular mortality in comparison to the general population. With the identification of new therapeutic targets and hypoglycemic drugs for T2DM, the need for a better stratification of CVD risk has emerged to select patients who may need intensive or specific treatment. At present, risk stratification is based on clinical, demographic, and biochemical factors. High sensitivity cardiac troponin (hs-cTn) increases after several ischemic and non-ischemic insults and it is considered a marker of myocardial injury. This review summarizes the main findings about hs-cTn utilization for risk stratification in people w…

0301 basic medicineDiabetes mellitumedicine.medical_specialtyendocrine system diseasesClinical BiochemistryPopulationSettore MED/49Biochemistrylaw.invention03 medical and health sciencesDiabetes mellitus0302 clinical medicineRandomized controlled triallawDiabetes mellitusmedicineHumansIn patientIntensive care medicineeducationLife StyleCardiovascular mortalityClinical Trials as Topiceducation.field_of_studyPrimary preventionbiologybusiness.industryBiochemistry (medical)Type 2 Diabetes MellitusBiomarkerGeneral MedicineCardiovascular diseasePrognosismedicine.diseaseTroponinTroponinSettore BIO/12 - Biochimica Clinica E Biologia Molecolare Clinica030104 developmental biologyRisk factorsDiabetes Mellitus Type 2Cardiovascular Diseases030220 oncology & carcinogenesisbiology.proteinObservational studyRisk factorbusinessBiomarkersClinica Chimica Acta
researchProduct

Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma

2016

The development of nucleic acid based vaccines against cancer has gained considerable momentum through the advancement of modern sequencing technologies and on novel RNA-based synthetic drug formats, which can be readily adapted following identification of every patient's tumor-specific mutations. Furthermore, affordable and individual ‘on demand’ production of molecularly optimized vaccines should allow their application in large groups of patients. This has resulted in the therapeutic concept of an active personalized cancer vaccine, which has been brought into clinical testing. Successful trials have been performed by intranodal administration of sterile isotonic solutions of synthetic …

0301 basic medicineDrugmedicine.medical_treatmentmedia_common.quotation_subjectBiomedical EngineeringMedicine (miscellaneous)Bioengineering02 engineering and technologyComputational biologyDevelopmentPharmacologyCancer VaccinesExcipients03 medical and health sciencesAntigens NeoplasmmedicineAnimalsHumansGeneral Materials ScienceRNA MessengerPrecision MedicineMelanomamedia_commonClinical Trials as TopicMessenger RNAbusiness.industryRNAImmunotherapy021001 nanoscience & nanotechnologyTumor antigenNanomedicine030104 developmental biologyLiposomesDrug deliveryNucleic acidNanoparticlesRNAImmunotherapyCancer vaccine0210 nano-technologybusinessNanomedicine
researchProduct

Genome-Wide Association Study for Serum Omega-3 and Omega-6 Polyunsaturated Fatty Acids: Exploratory Analysis of the Sex-Specific Effects and Dietary…

2020

Many early studies presented beneficial effects of polyunsaturated fatty acids (PUFA) on cardiovascular risk factors and disease. However, results from recent meta-analyses indicate that this effect would be very low or nil. One of the factors that may contribute to the inconsistency of the results is that, in most studies, genetic factors have not been taken into consideration. It is known that fatty acid desaturase (FADS) gene cluster in chromosome 11 is a very important determinant of plasma PUFA, and that the prevalence of the single nucleotide polymorphisms (SNPs) varies greatly between populations and may constitute a bias in meta-analyses. Previous genome-wide association studies (GW…

0301 basic medicineFatty Acid DesaturasesMaleSíndrome metabòlicaDiet MediterraneanMediterranean populationchemistry.chemical_compoundDelta-5 Fatty Acid DesaturaseÀcids grassos saturatsRisk Factorsgeneticschemistry.chemical_classificationMetabolic Syndromeeducation.field_of_studyClinical Trials as TopicNutrition and DieteticsbiologyMiddle AgedPhenotypeTreatment OutcomeFemaleomega-3mediterranean populationlcsh:Nutrition. Foods and food supplypolyunsaturated fatty acidsPolyunsaturated fatty acidmedicine.medical_specialtyomega-6FADS1Fatty Acid ElongasesLinoleic acidPopulationlcsh:TX341-641Single-nucleotide polymorphismGenetic polymorphismsPolymorphism Single NucleotideArticlemetabolic syndrome03 medical and health sciencesSex FactorsInternal medicineFatty Acids Omega-6Fatty Acids Omega-3medicinesexHumansGenetic Predisposition to DiseaseSaturated fatty acidseducationAgedgenome-wide association study030109 nutrition & dieteticsPolimorfisme genèticFatty acidmedicine.disease030104 developmental biologyFatty acid desaturaseEndocrinologyCross-Sectional StudieschemistrySpainbiology.proteinGene-Environment InteractionheterogeneityMetabolic syndromepolymorphismsFood ScienceGenome-Wide Association Study
researchProduct

Use of deep learning methods to translate drug-induced gene expression changes from rat to human primary hepatocytes

2020

In clinical trials, animal and cell line models are often used to evaluate the potential toxic effects of a novel compound or candidate drug before progressing to human trials. However, relating the results of animal and in vitro model exposures to relevant clinical outcomes in the human in vivo system still proves challenging, relying on often putative orthologs. In recent years, multiple studies have demonstrated that the repeated dose rodent bioassay, the current gold standard in the field, lacks sufficient sensitivity and specificity in predicting toxic effects of pharmaceuticals in humans. In this study, we evaluate the potential of deep learning techniques to translate the pattern of …

0301 basic medicineGene ExpressionGene Expression Regulation/drug effectsPathology and Laboratory MedicineConvolutional neural networkTOXICITYMachine LearningVoeding Metabolisme en GenomicaTime Measurement0302 clinical medicineGene expressionMedicine and Health SciencesMeasurementClinical Trials as TopicMultidisciplinaryArtificial neural networkPharmaceuticsQRMetabolism and GenomicsTOXICOGENOMICS030220 oncology & carcinogenesisMetabolisme en GenomicaMedicineEngineering and TechnologyNutrition Metabolism and GenomicsHepatocytes/drug effectsAlgorithmsResearch ArticleComputer and Information SciencesClinical Trials as Topic/statistics & numerical dataNeural NetworksGenetic ToxicologyTOXICOLOGYSciencePredictive ToxicologyComputational biologyBiologyComputer03 medical and health sciencesDose Prediction MethodsDeep LearningVoedingArtificial IntelligenceIn vivoGeneticsLife ScienceAnimalsHumansGeneNutritionbusiness.industryDeep learningBiology and Life SciencesGold standard (test)REPRESENTATIONSRats030104 developmental biologyGene Expression RegulationHepatocytesArtificial intelligenceNeural Networks ComputerToxicogenomicsbusinessNeuroscience
researchProduct

How can dementia and disability be prevented in older adults: where are we today and where are we going?

2021

Abstract Ageing of the population, together with population growth, has brought along an ample increase in the number of older individuals living with dementia and disabilities. Dementia is the main cause of disability in old age, and promoting healthy brain ageing is considered as a key element in diminishing the burden of age‐related disabilities. The World Health Organization recently launched the first risk reduction guidelines for cognitive impairment and dementia. According to recent estimates, approximately 40% of dementia cases worldwide could be attributable to 12 modifiable risk factors: low education; midlife hypertension and obesity; diabetes, smoking, excessive alcohol use, phy…

0301 basic medicineGerontologyPhysical disabilityPopulationReviewsReview030204 cardiovascular system & hematologyehkäisevä lääketiedelaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialpreventiontoimintakykylawRisk FactorsIntervention (counseling)Health careliikuntakykyInternal MedicineMedicineDementiaHumansCognitive DysfunctioneducationLife StyleDepression (differential diagnoses)cognitive impairmentAgedRandomized Controlled Trials as Topicmuistisairaudeteducation.field_of_studybusiness.industrymuscle physiologyliikuntarajoitteetCognitionriskitekijätmedicine.disease3. Good healthikääntyminen030104 developmental biologyageingDementiabusinessRisk Reduction BehaviorikääntyneetdementiaJournal of Internal Medicine
researchProduct

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

2018

The aim of this study was to evaluate cenicriviroc (CVC), a dual antagonist of C-C chemokine receptor types 2 and 5, for treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis. A randomized, double-blind, multinational phase 2b study enrolled subjects with NASH, a nonalcoholic fatty liver disease activity score [NAS] ≥4, and liver fibrosis (stages 1-3, NASH Clinical Research Network) at 81 clinical sites. Subjects (N = 289) were randomly assigned CVC 150 mg or placebo. Primary outcome was ≥2-point improvement in NAS and no worsening of fibrosis at year 1. Key secondary outcomes were: resolution of steatohepatitis and no worsening of fibrosis; improvement in fibrosis by ≥1 stag…

0301 basic medicineLiver CirrhosisMalePlacebo-controlled studyMedical Biochemistry and MetabolomicsGastroenterologyOral and gastrointestinallaw.inventionHepatitisNASH NAFLD CVC nonalcoholic fatty liver inflammationSteatohepatitis/Metabolic Liver Disease0302 clinical medicineRandomized controlled trialFibrosislawNon-alcoholic Fatty Liver DiseaseNonalcoholic fatty liver diseaseeducation.field_of_studyCVCLiver DiseaseNASHImidazolesMiddle AgedTreatment OutcomeTolerabilityLiverSulfoxides6.1 PharmaceuticalsCCR5 Receptor Antagonists030211 gastroenterology & hepatologyOriginal ArticleFemalePatient SafetyAdultmedicine.medical_specialtyPopulationChronic Liver Disease and CirrhosisClinical Trials and Supportive ActivitiesClinical SciencesImmunologyPlacebo03 medical and health sciencesDouble-Blind MethodClinical ResearchInternal medicineNAFLDmedicinenonalcoholic fatty liverHumanseducationAgedHepatologyGastroenterology & Hepatologybusiness.industryEvaluation of treatments and therapeutic interventionsOriginal Articlesmedicine.diseaseequipment and suppliesSurgeryCVC; NAFLD; NASH; inflammation; nonalcoholic fatty liver030104 developmental biologyinflammationHuman medicineSteatohepatitisbusinessDigestive DiseasesBiomarkers
researchProduct

Targeting Angiogenesis in Biliary Tract Cancers: An Open Option

2017

Abstract: Biliary tract cancers (BTCs) are characterized by a bad prognosis and the armamentarium of drugs for their treatment is very poor. Although the inflammatory status of biliary tract represents the first step in the cancerogenesis, the microenvironment also plays a key role in the pathogenesis of BTCs, promoting tumor angiogenesis, invasion and metastasis. Several molecules, such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), are involved in the angiogenesis process and their expression on tumor samples has been explored as prognostic marker in both cholangiocarcinoma and gallbladder cancer. Recent studies evaluated the genomic landscape of BTCs and…

0301 basic medicineMAPK/ERK pathwayVascular Endothelial Growth Factor AAngiogenesisDrug Evaluation PreclinicalTyrosine kinase inhibitorAngiogenesis InhibitorsReviewFibroblast growth factorCatalysiMetastasisAntineoplastic Agentlcsh:Chemistrychemistry.chemical_compoundangiogenesis0302 clinical medicinetyrosine kinase inhibitorsMolecular Targeted Therapylcsh:QH301-705.5SpectroscopyClinical Trials as TopicMonoclonal antibodieNeovascularization Pathologicvascular endothelial growth factorComputer Science Applications1707 Computer Vision and Pattern RecognitionGeneral MedicineComputer Science ApplicationsVascular endothelial growth factorGene Expression Regulation NeoplasticAngiogenesiChemistryBiliary Tract NeoplasmsTreatment OutcomeBiliary Tract Neoplasm030220 oncology & carcinogenesismonoclonal antibodiesTyrosine kinaseAngiogenesis InhibitorHumanSignal TransductionProtein Kinase InhibitorAntineoplastic Agentsbiliary tract cancersBiologyModels BiologicalAngiogenesis; Biliary tract cancers; Monoclonal antibodies; Tyrosine kinase inhibitors; Vascular endothelial growth factor; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biliary Tract Neoplasms; Clinical Trials as Topic; Drug Evaluation Preclinical; Gene Expression Regulation Neoplastic; Genetic Variation; Humans; Models Biological; Neovascularization Pathologic; Protein Kinase Inhibitors; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor A; Molecular Targeted Therapy; Catalysis; Molecular Biology; Spectroscopy; Computer Science Applications1707 Computer Vision and Pattern Recognition; Physical and Theoretical Chemistry; Organic Chemistry; Inorganic ChemistryCatalysisInorganic Chemistry03 medical and health sciencesIn vivomedicineAnimalsHumansPhysical and Theoretical ChemistryGallbladder cancerMolecular BiologyProtein Kinase InhibitorsBiologyAnimalOrganic ChemistryGenetic Variationmedicine.disease030104 developmental biologychemistrylcsh:Biology (General)lcsh:QD1-999Immunologyangiogenesis; biliary tract cancers; monoclonal antibodies; tyrosine kinase inhibitors; vascular endothelial growth factorCancer researchBiliary tract cancerInternational Journal of Molecular Sciences
researchProduct

Sulfur amino acid restriction, energy metabolism and obesity

2021

Abstract Background Dietary sulfur amino acid (SAA) restriction is an established animal model for increasing lifespan and improving metabolic health. Data from human studies are limited. In the study outlined in this protocol, we will evaluate if dietary SAA restriction can reduce body weight and improve resting energy expenditure (REE) and parameters related to metabolic health. Method/design Men and women (calculated sample size = 60), aged 18–45 years, with body mass index of 27–35 kg/m2 will be included in a double-blind 8-week dietary intervention study. The participants will be randomized in a 1:1 manner to a diet with either low or high SAA. Both groups will receive an equal base di…

0301 basic medicineMaleAdipose tissuePhysiologyUrineOverweightMETHIONINE RESTRICTIONchemistry.chemical_compound0302 clinical medicineProtocolMedicine030212 general & internal medicineAmino AcidsRandomized Controlled Trials as TopicRISKPLASMARGeneral MedicineMiddle AgedAmino Acids SulfurADIPOSE-TISSUEVDP::Medisinske Fag: 700::Helsefag: 800Body CompositionCYSTEINEMedicineFemaleLIFE-STYLEmedicine.symptomAdultAdolescentMetabolic healthAdipose tissueSulfur amino acidsGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesYoung AdultHumansResting energy expenditureObesityPlasma biomarkersMethioninebusiness.industryRepeated measures designTranslational researchmedicine.diseaseObesityPREVENTIONDietary intervention030104 developmental biologychemistryCysteine restrictionGene expressionbusinessEnergy MetabolismBody mass indexJournal of Translational Medicine
researchProduct

Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.

2015

Few patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) achieve prolonged disease-free survival. Blinatumomab, a bispecific T-cell engaging antibody construct, transiently links CD3-positive T cells to CD19-positive B cells. This phase 2 study evaluated stepwise (9-28-112 μg/d with weekly dose increases; n = 23) or flat (112 μg/d; n = 2) dosing of blinatumomab by continuous infusion, with dexamethasone prophylaxis, in patients with relapsed/refractory DLBCL. Patients received a median of 3 prior lines of therapy. Median time since last regimen was 1.5 months. Seventeen patients ended treatment in cycle 1 (induction), 7 in cycle 2 (consolidation), and 1 in retreatment. Am…

0301 basic medicineMaleCD3 ComplexClinical Trials and ObservationsSalvage therapyPhases of clinical researchKaplan-Meier EstimateBiochemistryGastroenterologyDexamethasone0302 clinical medicineRecurrenceAntibodies BispecificMedicineMolecular Targeted TherapyFatigueRemission InductionHematologyMiddle AgedTumor Burden030220 oncology & carcinogenesisBlinatumomabFemaleImmunotherapyLymphoma Large B-Cell Diffusemedicine.drugAdultmedicine.medical_specialtyFeverImmunologyAntigens CD19Antineoplastic AgentsDisease-Free SurvivalDrug Administration Schedule03 medical and health sciencesAntigens NeoplasmInternal medicineHumansDosingAdverse effectAgedSalvage TherapyDose-Response Relationship Drugbusiness.industryCell Biologymedicine.diseaseLymphomaSurgeryRegimen030104 developmental biologyNervous System DiseasesbusinessDiffuse large B-cell lymphomaBlood
researchProduct

Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus.

2021

International audience; Background: Recent years have witnessed a considerable increase in clinical trials of new investigational agents for Fabry disease (FD). Several trials investigating different agents are currently in progress; however, lack of standardisation results in challenges to interpretation and comparison. To facilitate the standardisation of investigational programs, we have developed a common framework for future clinical trials in FD.Methods and findings: A broad consensus regarding clinical outcomes and ways to measure them was obtained via the Delphi methodology. 35 FD clinical experts from 4 continents, representing 3389 FD patients, participated in 3 rounds of Delphi p…

0301 basic medicineMaleDelphi TechniqueEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]Delphi methodDisease030105 genetics & heredityKidneyBiochemistry0302 clinical medicineEndocrinologyClinical outcomesClinical Trials as TopicGlobosidesTrihexosylceramidesMiddle Aged3. Good healthClinical trialIsoenzymesTreatment OutcomeInclusion and exclusion criteriaSecondary Outcome MeasureFemaleAdultmedicine.medical_specialtyConsensusLysosomal storage disorders03 medical and health sciencesQuality of life (healthcare)Inherited metabolic disordersGeneticsmedicineHumansEnzyme Replacement TherapyIntensive care medicineMolecular BiologyFabry diseaseSphingolipidsbusiness.industryClinical study designmedicine.diseaseFabry diseaseClinical trialDelphi consensusalpha-GalactosidaseQuality of LifeFabry DiseaseGlycolipidsbusiness030217 neurology & neurosurgeryMolecular genetics and metabolism
researchProduct